Refocusing on Medication Safety: Best Practices for Injection Safety

Refocusing on Medication Safety: Best Practices for Injection Safety is organized by ProCE, Inc.,Release Date: December 22, 2021,Expiration Date: December 22, 2023,Description:,We learned a lot navigating our way through the global COVID-19 pandemic and as we define what will become the new normal it is imperative that medication safety efforts remain in focus. Healthcare practitioners have steered through disruptions in supplies, medications, personal protective equipment, and more, and continue to cope with staffing challenges and other stressors while striving to provide optimal patient care. Additionally, more than 90% of hospitalized patients receive some form of intravenous (IV) therapy, either by infusion or IV push administration. IV medications are known to be clinically advantageous due to their immediate therapeutic effect and ability to support plasma drug levels, and patients being treated for COVID-19 often require multiple high-alert medications. Unfortunately, these practices are not without risk. ,With harmful outcomes at stake, ISMP believes it is essential to provide healthcare practitioners with relevant information to assist them in identifying and managing the risks. ,This webinar will focus on the challenges of the global COVID-19 pandemic, how practitioners can prevent medication errors despite this disruption, how to refocus on best practices related to IV push medications in adults, and how these strategies can have additional workflow benefits.,Learning Objectives:,Upon completion of this activity, participants will be able to:,• Identify how stressors, such as the COVID-19 pandemic, challenge medication safety efforts.,• Considering pandemic-related disruptions, list strategies to prevent medication errors, including the use of ready-to-administer preparations.,• Describe three best practices for the use of IV push medications.,• Explain how best practices for IV push medications can provide additional workflow benefits.